GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. The company is advancing its GEO-MVA vaccine candidate toward a planned pivotal immunobridging study under an expedited regulatory pathway, while also progressing its Gedeptin immuno-oncology program.
During the second quarter, GeoVax continued operational activities in preparation for the expected fourth-quarter initiation of the GEO-MVA pivotal study, which is designed to demonstrate non-inferiority to an approved MVA vaccine. These activities included clinical study readiness, manufacturing preparedness, and engagement with government and public health stakeholders. The company has already manufactured and released cGMP clinical trial material and is advancing the AGE1 continuous cell-line manufacturing platform for future commercial-scale production.
GeoVax believes GEO-MVA is uniquely positioned to address the growing need for diversified global MVA vaccine manufacturing capacity, supporting public health preparedness and biodefense resilience. The company has engaged with government and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
In addition to its infectious disease program, GeoVax is advancing Gedeptin, an investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies like Keytruda (Merck). GeoVax continues to strengthen the program's strategic positioning through its exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4,426,578, or $0.97 per share, for the three months ended June 30, 2026, compared to a net loss of $5,369,783, or $8.74 per share, for the same period in 2025. The decrease in net loss was primarily due to lower research and development expenses, which fell to $3,110,508 from $4,728,998, reflecting reduced costs associated with the discontinued GEO-CM04S1 COVID-19 vaccine program. In May 2026, the company announced a strategic reprioritization to focus resources on GEO-MVA and Gedeptin, discontinuing active development of its COVID-19 vaccine candidate due to market contraction.
General and administrative expenses also decreased to $1,331,564 from $1,542,190, primarily due to lower investor relations consulting costs and reduced stock-based compensation. The company reported cash balances of approximately $3.1 million as of June 30, 2026, unchanged from December 31, 2025.
GeoVax's strategic priorities include execution of the GEO-MVA pivotal immunobridging clinical program, advancement of scalable continuous cell-line manufacturing capabilities, engagement supporting future government and international procurement opportunities, advancement of Gedeptin combination immunotherapy strategies, and disciplined capital deployment. The company believes these programs offer the strongest combination of clinical differentiation, regulatory clarity, and commercial opportunity.
The impact of this announcement is significant for the biodefense and public health preparedness landscape. If successful, GEO-MVA could provide an additional, diversified source of MVA vaccine for protection against mpox and smallpox, addressing critical global supply needs. In oncology, Gedeptin's potential to enhance immune checkpoint inhibitor therapy could improve outcomes for patients with immunologically resistant tumors, representing a meaningful advancement in cancer treatment.
